Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study

January 23, 2026Rheumatology and TherapyOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to assess how guselkumab affects patient-reported outcomes in individuals with psoriatic arthritis who did not respond adequately to TNF inhibitors.
Conducted a clinical trial (COSMOS Study) with participants having inadequate response to TNF inhibitors.
Administered guselkumab to assess its impact on patient-reported outcomes.
Evaluated outcomes using standardized questionnaires before and after treatment.
Participants reported significant improvements in symptoms and overall quality of life after treatment with guselkumab.
The improvements were evident in multiple domains of patient-reported outcomes.
Guselkumab demonstrated a more favorable response than previous TNF inhibitor therapies.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Clinical trial shows guselkumab improves outcomes in psoriatic arthritis, indicating effective treatment for non-responders.

ClinicalTrials.gov identifier, NCT03796858.

No takes yet. Share an insight, caveat, or question.

Gossec et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share